Compare BridgeBio Pharma Inc (BBIO) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Royal Caribbean Cruises Ltd — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while Royal Caribbean Cruises Ltd trades at $283.32 (market cap $75.92B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 4.6× BridgeBio Pharma Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.77% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | RCL | |
|---|---|---|
Market Cap | $16.46B | $75.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $365.84 |
52-Week Low | $44.81 | $246.71 |
Enterprise Value | $18.02B | $97.20B |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Royal Caribbean (RCL) trades at $288.61, up 1.14% today, with a bullish technical setup near key resistance at $292. The company demonstrates strong fundamental momentum, with 2025 revenue reaching $17.93 billion and net income surging to $4.27 billion, yielding a robust 24.36% net margin. Analyst consensus is positive, with a $328 price target implying 14% upside, supported by 25 buy ratings. Recent news highlights Caribbean demand strength offsetting European softness, with Q2 2026 earnings due July 28.
RCL's outlook is favorable, driven by earnings beats, expanding margins, and strategic destination investments. Key risks include Europe demand volatility, high debt levels, and competitive pressures. Institutional sentiment leans bullish, but macroeconomic sensitivity and execution on yield growth remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
